C
RXRX icon

Covestor’s Recursion Pharmaceuticals RXRX Stock Holding History

Covestor’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
120
+85
+243% +$283 ﹤0.01% 2793
2026
Q1 		$0 Buy
35
+16
+84% +$62 ﹤0.01% 2704
2025
Q4 		$0 Hold
19
– – ﹤0.01% 2674
2025
Q3 		$0 Hold
19
– – ﹤0.01% 2699
2025
Q2 		$0 Sell
19
-2
-10% -$10 ﹤0.01% 2675
2025
Q1 		$0 Hold
21
– – ﹤0.01% 2658
2024
Q4 		$0 Buy
21
+9
+75% +$61 ﹤0.01% 2664
2024
Q3 		$0 Sell
12
-1
-8% -$7 ﹤0.01% 2680
2024
Q2 		$0 Hold
13
– – ﹤0.01% 2677
2024
Q1 		$0 Sell
13
-1
-7% -$11 ﹤0.01% 2660
2023
Q4 		$0 Sell
14
-2
-13% -$14 ﹤0.01% 2633
2023
Q3 		$0 Sell
16
-2
-11% -$20 ﹤0.01% 2623
2023
Q2 		$0 Hold
18
– – ﹤0.01% 2574
2023
Q1 		$0 Hold
18
– – ﹤0.01% 2498
2022
Q4 		$0 Sell
18
-2
-10% -$20 ﹤0.01% 2519
2022
Q3 		$0 Sell
20
-12
-38% -$122 ﹤0.01% 2501
2022
Q2 		$0 Buy
32
+7
+28% +$47 ﹤0.01% 2298
2022
Q1 		$0 Sell
25
-7
-22% -$74 ﹤0.01% 2399
2021
Q4 		$1K Buy
+32
New +$602 ﹤0.01% 1909

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Covestor's RXRX Position: Q2 2026 in Review

Covestor increased its Recursion Pharmaceuticals (RXRX) stake by 243% in Q2 2026, buying an estimated $283 and bringing the position to 120 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2793.

Covestor first reported a position in RXRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $1K in Q4 2021. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Covestor held 120 shares of Recursion Pharmaceuticals worth $0 as of Q2 2026.
  • Covestor bought 85 Recursion Pharmaceuticals shares in Q2 2026, an estimated $283.
  • Recursion Pharmaceuticals made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2793 holding.
  • Covestor first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • Covestor's Recursion Pharmaceuticals position peaked at $1K in Q4 2021.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.